Subsidies & Funding

We empower medical innovation

Project Management

We manage your EU Horizon 2020 project

Business Strategy

We support successful commercialisation

Funding database

EU & non EU subsidies


Other EU Subsidies

Wellcome Trust's vision is to achieve extraordinary improvements in human and animal health. In pursuit of this, they support the brightest minds in biomedical research and the medical humanities. In the 2012/2013 financial year, Wellcome Trust funded 927 new grants and 235 supplementary / enhancement grants with a total value of £559M (€ 705M), over 85%  of which went to science funding. The award rate (number of awards divided by number of applications) between 2008 and 2013 has been between 20 and 25%.

Areas of research

Wellcome Trust has identified five major challenge areas for the 2010 - 2020 period. Funding from the past four years has been divided over these areas as follows:

  • Genetics and genomics - £ 240M / 9.2%
  • Understanding the brain - £ 474M / 18.2%
  • Combating infectious disease - £ 568M / 21.8%
  • Development, ageing and chronic disease - £ 868M / 33.4%
  • Environment, nutrition and health - £ 28M / 1.1%
  • Cross-challenge - £ 423M / 16.3%

Biomedical science grant applications

Selected biomedical science grants are listed in the tables below.

Business grants

  • Translational Fund (500k - 5M)
  • Seeding Drug Discovery (1 - 2M)
  • Health Innovation Fund
  • Pathfinder Award (100k - 350k)

Academic grants

  • Investigator Awards (3M)
  • Seed Awards (100k)
  • Fellowships (salary + bench fee)
  • Collaborative Awards (4M)

Additionally, varying strategic awards and themed initiatives are offered, which may be found here.

An extensive grant deadlines calendar is provided here.

Eligible applicants for academic research grants are based at higher education or research institutions in the UK, Ireland or low- or middle-income countries. Companies that apply for innovation research have to be based in the UK, but collaborations with international partners are allowed.

Funding framework

(from the Wellcome Trust website)

Strategic funding is available in research areas that we judge to be strategically important, informed by dialogue with our researchers and the wider community. Applications will be invited, but we welcome the opportunity to discuss research ideas that might fit with our strategic priorities, and that might be suitable for an invitation. Final awards under our current Strategic Awards scheme will be made in July 2015.

Responsive funding, which represents the majority, is divided into five categories that run across our Science, Innovations, Medical Humanities, Society and Ethics, and Engaging Science funding.

The five categories are people, seeds, teams, places and resources.


We believe that breakthroughs emerge when talented researchers are given the resources and freedom they need to pursue their goals. We will continue to offer personal support to researchers through schemes such as Investigator Awards and fellowships.

Our New Investigator and Senior Investigator Award schemes have been merged into single Investigator Award schemes specific to Science, Medical Humanities or Society and Ethics. All candidates will continue to be considered according to their career stage and experience to date.

We have increased funding opportunities available through our Sir Henry Wellcome Postdoctoral Fellowship and Sir Henry Dale Fellowship schemes.


This is a new kind of funding to support the generation of new ideas. It aims to address a gap identified by our community: small awards to investigate riskier concepts.

Seed Awards in Science, Medical Humanities and Society and Ethics provide funding to develop original and innovative ideas, enabling researchers to generate preliminary data, resources, networks, tools or archival research towards a larger research application.

In Innovations, our updated Pathfinder Awards offer pilot funding to catalyse innovative early-stage applied research and development projects in areas of unmet medical need to develop assets and de-risk future development.

Within public engagement, we offer seed funding through our Development Awards (Broadcast, Games and Film) and we have increased the cap on seed funding available through our People Awards and Small Arts Awards.


We recognise that collaboration is a key component of a vibrant research environment. It promotes the development of new ideas and can bring different disciplines together to speed up the pace of discovery. We have developed a new kind of funding for collaborative research.

Collaborative Awards in Science, Medical Humanities and Society and Ethics provide groups of researchers with the support to pursue key research questions where a team effort is required.

Portfolio Awards support collaborative research and technology development by funding programmes which require a portfolio of projects to deliver leading-edge innovations in healthcare.

The call for Collaborative Awards will open in the new year.

We continue to support innovative projects that engage and involve the public with biomedical science through existing programmes and our new Sustaining Excellence Awards, which support the enhanced delivery of outstanding public engagement work.


To ensure that researchers can work and train in world-class environments, we continue to provide long-term support for centres of excellence in the UK and in low- and middle-income countries.


This support provides funding for shared equipment, facilities and research resources, including support for longitudinal studies.

ttopstart can help you apply for funding at Wellcome Trust

ttopstart has extensive experience in the support of applications for complex subsidy programmes such as that of the Wellcome Trust. ttopstart can help identify a program and funding opportunity and perform a thorough feasibility assessment prior to preparing a full application. Our services for Wellcome Trust subsidies are largely comparable to those of Horizon 2020. Please contact us for more information.


ir. Jasper Levink

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative and aims to speed up the development of better and safer medicines for patients. 

About the Innovative Medicines Initiative

The new IMI2 JTI started in January 2014. It will bring together the members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), universities, public laboratories, innovative SMEs, patient groups and regulators. IMI intends to pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges through a concentrated and combined science and innovation effort. As such it will help secure the future international competitiveness of Europe’s pharmaceutical industry. 

IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators to tackle important challenges in medicine.

Increase your chances of success at IMI with ttopstart

ttopstart has supported different successful IMI proposals. One of them was ranked as #1 by both the scientific and industrial review board. Please contact us for more information regarding IMI.


ir. Jasper Levink

The European Investment Bank (EIB) is the biggest multilateral borrower and lender of the world, and aims to improve the quality of life for people in Europe and beyond.

About the European Investment Bank Group

The European Investment Bank was founded in Brussels in 1958. 90% of its activities are in Europe, although since 1960 partnerships have been established with countries outside the EU. With EU Member States as its shareholders, the EIB provides finance for sustainable investment projects that should contribute to objectives posed by EU policy.

EIB's activities take place in its four main priorities: innovation and skills, small and medium enterprises, infrastructure, and environment. General objective in all priorities is to support both job creation as well as sustainable growth. The EIB supports a wide range of sectors, including "Health and life science", "Agriculture, food and rural development" and more.


Lending is EIB's main activity. Financing here includes loans (project and intermediated), microfinance, venture capital, and equity and fund investment. The money that EIB lends is acquired through bond issues, and due to its outstanding credit rating this results in good rates for its borrowers. Typically, around one-third of total project costs can be financed through EIB lending. Usually, the support by the EIB is the first step in attracting other investors, thereby creating a multiplier effect.


Blending is a combination of EIB loans or services with funding opportunities from other resources, in order to provide a full financing service. For example, Blending can help projects that otherwise would have a risk profile that is too high. Blending forms are partly provided by the European Investment Fund (EIF), which has expertise in SME finance.

There are many different types of blended financing. Examples of these are guarantees, projects bonds, trust funds and many more. InnovFin is an example of a Blending form, that is of special interest to Life Science entrepreneurs through InnovFin Infectious Diseases.


In order to complement the Lending activities, the EIB also offers advisory services through the European Investment Advisory Hub – which aims to ensure improved knowledge sharing as well as guidance to the right people for your project specifically. Both technical and financial expertise is made available, which in turn can strengthen the technical and economic foundations of an investment.

Request assistance

ttopstart can support your applications to the EIB. Contact us today to find out the possibilities.